MX2022006877A - Uso de un abridor de canal de potasio kv7 para tratar el dolor. - Google Patents

Uso de un abridor de canal de potasio kv7 para tratar el dolor.

Info

Publication number
MX2022006877A
MX2022006877A MX2022006877A MX2022006877A MX2022006877A MX 2022006877 A MX2022006877 A MX 2022006877A MX 2022006877 A MX2022006877 A MX 2022006877A MX 2022006877 A MX2022006877 A MX 2022006877A MX 2022006877 A MX2022006877 A MX 2022006877A
Authority
MX
Mexico
Prior art keywords
treating pain
potassium channel
channel opener
methods
subject
Prior art date
Application number
MX2022006877A
Other languages
English (en)
Spanish (es)
Inventor
Gregory N Beatch
Jr James Philip Johnson
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MX2022006877A publication Critical patent/MX2022006877A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Guides In General And Applications Therefor (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
MX2022006877A 2019-12-06 2020-12-04 Uso de un abridor de canal de potasio kv7 para tratar el dolor. MX2022006877A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US201962948010P 2019-12-13 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (1)

Publication Number Publication Date
MX2022006877A true MX2022006877A (es) 2022-07-11

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006877A MX2022006877A (es) 2019-12-06 2020-12-04 Uso de un abridor de canal de potasio kv7 para tratar el dolor.

Country Status (14)

Country Link
EP (1) EP4069211A1 (enExample)
JP (1) JP2023504166A (enExample)
KR (1) KR20220113411A (enExample)
CN (1) CN114786658A (enExample)
AU (1) AU2020397173A1 (enExample)
BR (1) BR112022010733A2 (enExample)
CA (1) CA3159436A1 (enExample)
CL (1) CL2022001477A1 (enExample)
CR (1) CR20220318A (enExample)
IL (1) IL293504A (enExample)
MX (1) MX2022006877A (enExample)
PE (1) PE20221169A1 (enExample)
TW (1) TW202133847A (enExample)
WO (1) WO2021113757A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US7553858B2 (en) * 2003-12-17 2009-06-30 Meda Pharma Gmbh & Co. Kg Combination of flupirtine and tramadol
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
MA52569B1 (fr) * 2018-05-11 2023-11-30 Xenon Pharmaceuticals Inc Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant

Also Published As

Publication number Publication date
PE20221169A1 (es) 2022-07-25
WO2021113757A1 (en) 2021-06-10
AU2020397173A1 (en) 2022-06-23
EP4069211A1 (en) 2022-10-12
CN114786658A (zh) 2022-07-22
KR20220113411A (ko) 2022-08-12
TW202133847A (zh) 2021-09-16
CA3159436A1 (en) 2021-06-10
BR112022010733A2 (pt) 2022-08-23
CR20220318A (es) 2022-10-07
CL2022001477A1 (es) 2023-04-28
JP2023504166A (ja) 2023-02-01
IL293504A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MX2023013247A (es) Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje.
MX2022005490A (es) Metodos para el tratamiento de trastornos depresivos.
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
MX2023009314A (es) Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
MX2025002705A (es) Isoquinolonas como inhibidores de pi3k
MX2023005658A (es) Formulaciones de gel, ungüento y espuma de tapinarof y metodos de uso.
MX2024015077A (es) Benzopirimidina-4(3h)-onas como inhibidores de pi3k
MX2025005318A (es) Compuesto de cucurbiturilo y uso medico del mismo
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
MX2025005597A (es) Compuestos antisenescencia novedosos y composiciones de los mismos
MX2022003845A (es) Tratamientos cognitivos medicinales.
CL2022001477A1 (es) Uso de un abridor de canal de potasio kv7 para tratar el dolor
GEP20247629B (en) Alcohol derivatives as kv7 potassium channel openers
MX2023009313A (es) Terapia conjunta para el tratamiento de trastornos convulsivos.
PH12022553502A1 (en) Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine
WO2023019095A3 (en) Momelotinib combination therapy
NZ787838B2 (en) Methods of treating depressive disorders
AR026506A1 (es) Un medicamiento para la prevencion y el tratamiento de la disfuncion sexual
WO2025034812A3 (en) Trifluoroborate (bf3) compositions for use in boron neutron capture therapy and methods thereof
NZ788497A (en) Use of reboxetine to treat nervous system disorders
JOP20240255A1 (ar) مثبطات الفيروس المخلوي للجهاز التنفسي البشري وفيروس الميتانيمو
ZA202305888B (en) Novel therapeutic composition based on essential oils at low doses